enzalutamide
pfizer,astellas
['enzamet', 'prostate']
#asco22 ironically, enzamet provides the best evidence yet that docetaxel layered on ar targeted therapy is still valuable for patients with the poorest prognosis (ie high volume, synchronous prostate cancer). os benefit seen in the first 2-3 years only 
Genitourinary oncologist 
#LevineCancerInstitute
@AtriumHealth
Views are my own
RT is not an endorsement